To evaluate whether early changes in anti-PLA2R antibody titers, 24-h urine protein quantification, and serum albumin levels can predict 12-month remission in membranous nephropathy (MN) and to develop a nomogram model for clinical decision-making.
Approach:
Statistical Methods: Risk factors were identified using Lasso-Logistic regression; a nomogram was constructed and evaluated using receiver operating characteristic (ROC) curves and calibration plots.
Key Findings:
1-month urinary protein (OR = 1.374), anti-PLA2R decline (OR = 0.944), and albumin increase (OR = 0.967) were identified as independent predictors of remission.
Interpretation:
Dynamic changes in anti-PLA2R antibodies, urinary protein, and serum albumin at 1 month are effective predictors of 12-month remission in MN.
Limitations:
Retrospective design may introduce selection bias.
Single-center study limits generalizability of findings.
Conclusion:
The nomogram model enables early risk stratification and optimization of personalized treatment strategies for MN.
Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.
